Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2013-04-24 Investor Presentation
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Investor Presentation 2013
Investor Presentation Classification · 99% confidence The document is a detailed analysis report published by an analyst firm ('Montega') on April 24, 2013, concerning the company EVOTEC AG. It includes stock recommendations ('Kaufen'), price targets, performance data, shareholder structure, future dates (like Q1 2013 report and AGM), financial forecasts (2013e, 2014e, 2015e), and extensive commentary on pipeline progress (Diabetes, Alzheimer) and business strategy. This structure—including analyst contact information, publication date, and investment recommendation—is characteristic of an Investment Research or Analyst Report. Since 'Investment Presentation' (IP) is for company-generated presentations, and 'Earnings Release' (ER) is for initial results, this document, being a third-party analysis with forecasts and recommendations, best fits the general 'Investor Presentation' (IP) category if a specific 'Analyst Report' category is unavailable, or perhaps 'Investor Presentation' (IP) as it presents investment rationale. However, given the depth and structure, it strongly resembles a comprehensive research report. Reviewing the definitions, 'Investor Presentation' (IP) is the closest fit for detailed investment rationale and pipeline review, although it is not strictly a company-issued presentation. Since there is no explicit 'Analyst Report' code, and it contains detailed financial projections and strategic analysis intended for investors, 'IP' (Investor Presentation) is the most appropriate classification among the choices provided for a detailed investment thesis document.
2013-04-24 German
Evotec extends drug discovery alliance with Genentech
Regulatory Filings Classification · 100% confidence The document is a short press release dated April 22, 2013, announcing the extension of a drug discovery alliance between Evotec AG and Genentech. It contains key highlights, quotes, and boilerplate information, typical of a corporate news announcement. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since it is a general corporate announcement disseminated via DGAP (a service for regulatory announcements, financial news, and press releases) and does not fit into the more specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate classification is the general Regulatory Filings category (RNS), which serves as a fallback for miscellaneous corporate news releases that aren't covered elsewhere, especially when they are not explicitly an Earnings Release (ER) or a Report Publication Announcement (RPA). Given the content is a strategic business update, RNS is the best fit among the available options.
2013-04-22 English
Earnings Release 2012
Earnings Release Classification · 99% confidence The document provides a detailed analysis of Evotec AG's financial performance for the fiscal year 2012, including revenue, margins, EBIT, cash flow, and forward-looking guidance for 2013. It contains tables summarizing historical and projected financial data (Umsatz, EBIT, EPS, Margins) and discusses specific operational results (e.g., weak Q4, impairment write-down related to Pfizer). This structure—reviewing past performance and providing detailed outlook/guidance—is characteristic of a comprehensive financial report or an analyst report based on such a report. Since the text analyzes the reported figures (87.3 Mio. Euro revenue for 2012) and provides detailed forecasts ('Prognosen Anpassung' and 'Ausblick 2013'), it is not merely an announcement (RPA/RNS) but the content of a report. Given the comprehensive nature covering the full fiscal year and outlook, it aligns best with an Interim/Quarterly Report (IR) if it were quarterly, or an Annual Report (10-K) if it were the official filing. However, the presence of analyst commentary ('Empfehlung: Kaufen', analyst contact details, and comparison to guidance) strongly suggests this is an Analyst Report or a detailed Management Discussion & Analysis (MDA) section derived from the annual results. Since the document focuses heavily on explaining the results, trends, and outlook ('Schwaches viertes Quartal, Dynamik bei Kundenakquise und Kommerzialisierung weiter intakt' and detailed discussion of margins and cash flow), it fits the definition of Management Reports (MDA) very well, which covers management's detailed explanation of financial results, business trends, and outlook. It is too detailed to be just an Earnings Release (ER) and lacks the formal structure of a 10-K, appearing more like an analyst's deep dive or the management commentary section. FY 2012
2013-04-03 German
Earnings Release 2012
Earnings Release Classification · 99% confidence The document is titled 'Eine Research-Publikation der DZ BANK AG' concerning the company Evotec. It contains detailed financial tables, historical data (2012), estimates (2013e-2015e), valuation metrics, peer comparisons, and an investment recommendation ('Kaufen' - Buy) with a stated Fair Value. This structure is characteristic of an equity research report or an investment analysis document, not an official regulatory filing like a 10-K, ER, or IR. Since 'Research-Publikation' is not an explicit category, I must select the closest fit. The document provides comprehensive financial analysis and outlook, which aligns best with an Investor Presentation (IP) or a detailed Management Discussion & Analysis (MDA) if it were a company filing. However, as a third-party research publication, it functions as detailed investment guidance. Given the options, 'Investor Presentation' (IP) is the closest proxy for a detailed, forward-looking analysis document, although 'RPA' (Report Publication Announcement) or 'RNS' (Regulatory Filings) are possibilities if this were merely an announcement *of* the research. Since the text *is* the research content itself (detailed analysis, tables, recommendation), and it is not a standard regulatory form, 'Investor Presentation' (IP) is the most appropriate classification for a detailed, non-official analytical document provided to investors, even though it is third-party research. Given the depth of financial data and forward estimates, it is more substantial than a simple factsheet (FS). I will classify it as Investor Presentation (IP) as it serves a similar function of presenting investment rationale and data. FY 2012
2013-03-28 German
Evotec AG: Forward step by step with Action Plan 2016 - Continued revenue growth - Significant pipeline progress
Earnings Release Classification · 100% confidence The document explicitly states that Evotec AG is reporting 'financial results and corporate updates for the fiscal year ended 31 December 2012.' It provides detailed financial figures (Revenues, Operating result, Net income, Cash flow) for the full year, along with operational performance summaries and guidance for the next year (2013). This content structure is characteristic of an Annual Report or a comprehensive summary thereof. Although it is presented as a press release announcing the results, the depth and scope of the financial data provided (covering the entire fiscal year) strongly suggest it is the primary disclosure of the annual results, which aligns best with the '10-K' category, which covers official yearly reports. However, since this is a press release format announcing the results and includes a webcast/conference call section, it is often classified as an Earnings Release (ER) or a comprehensive report. Given the mention of 'fiscal year ended 31 December 2012' and the comprehensive nature, it is more than just an 'Earnings Release' (ER) which is usually quarterly highlights. It is the full annual disclosure. In the context of the provided definitions, '10-K' is for the 'Official yearly report covering company activity and full financial performance.' While this is a press release, it contains the substance of the annual report. If a separate 10-K filing exists, this document functions as the primary public announcement of those results. Given the comprehensive nature covering the full fiscal year, 10-K is the most appropriate classification for the *content type*, even if the *format* is a press release. If the document were significantly shorter and only pointed to the full report, RPA would be chosen. Since it contains the full details, 10-K is selected. FY 2012
2013-03-26 English
Annual Financial Statements 2012
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2012' and contains comprehensive sections typical of a full annual report, including a letter to shareholders, corporate governance, management reports, and references to consolidated financial statements. It is a long-form document (over 500,000 characters) that provides a detailed review of the company's performance, strategy (Action Plan 2016), and financial outlook for the fiscal year 2012, fitting the definition of an Annual Report. FY 2012
2013-03-26 German

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.